Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Athira Pharma, Inc. (ATHA)

    Price:

    3.92 USD

    ( - -0.03 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    ATHA
    Name
    Athira Pharma, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    3.920
    Market Cap
    15.460M
    Enterprise value
    -24.633M
    Currency
    USD
    Ceo
    Mark J. Litton
    Full Time Employees
    26
    Website
    Ipo Date
    2020-09-18
    City
    Bothell
    Address
    18706 North Creek Parkway

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    76.562B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    4.706B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    122.616B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.410
    P/S
    0
    P/B
    0.577
    Debt/Equity
    0.034
    EV/FCF
    0.086
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -2.440
    Debt/assets
    0.030
    FUNDAMENTALS
    Net debt/ebidta
    0.527
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    0
    Capex to revenue
    0
    Capex to depreciation
    0
    Return on tangible assets
    -1.256
    Debt to market cap
    0.059
    Piotroski Score
    1.000
    FUNDAMENTALS
    PEG
    -0.011
    P/CF
    -0.295
    P/FCF
    -0.295
    RoA %
    -125.605
    RoIC %
    -141.768
    Gross Profit Margin %
    0
    Quick Ratio
    9.697
    Current Ratio
    9.697
    Net Profit Margin %
    0
    Net-Net
    5.573
    FUNDAMENTALS PER SHARE
    FCF per share
    -13.272
    Revenue per share
    0
    Net income per share
    -9.565
    Operating cash flow per share
    -13.272
    Free cash flow per share
    -13.272
    Cash per share
    6.396
    Book value per share
    6.792
    Tangible book value per share
    6.792
    Shareholders equity per share
    6.792
    Interest debt per share
    0.231
    TECHNICAL
    52 weeks high
    6.090
    52 weeks low
    2.200
    Current trading session High
    4.132
    Current trading session Low
    3.860
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -6.414769%
    P/E
    -0.002
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.334
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.502
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.310
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.797
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.117
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.628
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.136
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.612
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.177
    DESCRIPTION

    Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

    NEWS
    https://images.financialmodelingprep.com/news/generation-uranium-applauds-atha-energys-uranium-discoverys-in-the-20251211.jpg
    Generation Uranium Applauds ATHA Energy's Uranium Discoverys In The Angikuni Basin, South Of Generations YATH Project

    thenewswire.com

    2025-12-11 08:30:00

    Vancouver, British Columbia – December 11, 2025 – TheNewswire - Generation Uranium Inc. (TSXV:GEN, OTCQB: GENRF) (the “Company” or “Generation”) is pleased to see Atha Energy's success in exploration in the Angikuni Basin located south of the Companies Yath Project. Atha has now reported multiple discoveries at the RIB target area on November 20 th and December 10, 2025. All exploration drill holes at the RIB zone intersected uranium mineralization, (Atha press release, Dec 10, 2025) with up to 5.55% U3O8. These discoveries are a clear demonstration of both the Angikuni Basin's uranium potential and also the hard work and effective exploration of the Atha Energy team.

    https://images.financialmodelingprep.com/news/athena-gold-closes-first-tranche-of-nonbrokered-private-placement-20251209.jpg
    Athena Gold Closes First Tranche of Non-Brokered Private Placement and Announces Further Upsize

    accessnewswire.com

    2025-12-09 07:00:00

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BC / ACCESS Newswire / December 9, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of the first tranche of a non-brokered private placement previously announced on November 14, 2025, as amended November 24, 2025, to raise up to CDN $3,100,000 (the "Offering"). An aggregate of CDN $2,727,526.03 has been raised in the first tranche consisting of the following: CDN $1,331,801.03 through the issuance of 19,025,729 flow-through units (the "FT Units") at a price of CDN $0.07 per FT Unit; CDN $1,015,500.08 through the issuance of 14,507,144 flow-through common shares (the "CMETC FT Shares) at a price of CDN $0.07 per CMETC FT Share; and CDN $380,224.92 through the issuance of 6,337,082 non-flow-through unit (the "NFT Units") at a price of CDN $0.06 per NFT Unit.

    https://images.financialmodelingprep.com/news/athena-gold-provides-exploration-update-from-excelsior-goldsilver-project-20251126.jpg
    Athena Gold Provides Exploration Update From Excelsior Gold-Silver Project, Nevada

    accessnewswire.com

    2025-11-26 07:00:00

    Maiden diamond drilling returns 4.33 g/t Au over 14.4m; geophysics defines large intrusive WHITE ROCK, BC / ACCESS Newswire / November 26, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada. Mammoth Minerals Limited (ASX:M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest in the project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see press releases dated June 2, 2025, and August 22, 2025).

    https://images.financialmodelingprep.com/news/atha-energy-confirms-new-highgrade-discovery-at-angilak-project-20251120.jpg
    ATHA Energy Confirms New High-Grade Discovery at Angilak Project - Rib North, Maiden Hole Returns Assays with 34.7 m of Total Composite Uranium Mineralization, Including 13.6 m Grading 0.53% U3O8, 1.1 m Grading 4.81% U3O8, and Grades Up to 8.16% U3O8

    accessnewswire.com

    2025-11-20 07:00:00

    HIGHLIGHTS Assays confirm the Company's maiden drillhole, RIBN-DD-001, at the RIB North Discovery as the best exploration hole drilled to date at the Angilak Uranium Project; RIBN-DD-001 assays returned total composite uranium mineralization1 of 34.7 m encompassing seven zones from 287.0 m to 439.9 m (Figure 4) - surpassing what was reported in the release of preliminary results (September 23rd, 2025, News Release ); The widest continuous intersection in the hole - from 426.3 to 439.9 - returned 13.6 m of composite uranium mineralization1 grading 0.53% U3O8, including 1.1 m grading 4.81% U3O8 with the highest-grade sample returning 8.16% U3O8 over 0.5 m; Mineralization was first intersected in the sandstone over three intervals (between 287.0 m and 351.1 m). The fourth zone was intersected directly above the unconformity (located at 356.7m), extending into graphitic basement rock below.

    https://images.financialmodelingprep.com/news/atha-announces-filing-of-a-final-short-form-prospectus-20251031.jpg
    ATHA Announces Filing of a Final Short Form Prospectus

    accessnewswire.com

    2025-10-31 14:45:00

    Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 31, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), is pleased to announce that, further to its press release dated October 21, 2025, the Company has filed its final short form prospectus (the "Prospectus") with the securities commissions in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and New Brunswick and been issued a receipt (the "Receipt") by the British Columbia Securities Commission, as principal regulator, in connection with the qualification of up to 18,838,752 units (the "Units") of the Company issuable upon the exercise or deemed exercise of 17,126,138 special warrants ("Special Warrants") of the Company issued in connection with its previously announced private placement.

    https://images.financialmodelingprep.com/news/atha-announces-filing-of-annual-information-form-and-preliminary-short-20251021.jpg
    ATHA Announces Filing of Annual Information Form and Preliminary Short Form Prospectus

    accessnewswire.com

    2025-10-21 22:25:00

    Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / ATHA Energy Corp. (TSX.V:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), is pleased to announce that, further to its press releases dated September 18, 2025 and August 11, 2025, the Company has filed its annual information form for the fiscal year ended December 31, 2024 (the "AIF"), and a preliminary short form prospectus (the "Prospectus") with the securities commissions in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and New Brunswick, in connection with the proposed qualification of up to 18,838,752 units (the "Units") of the Company issuable upon the exercise or deemed exercise of 17,126,138 special warrants ("Special Warrants") of the Company issued in connection with its previously announced private placement.

    https://images.financialmodelingprep.com/news/atha-clarifies-technical-disclosure-and-files-an-amended-technical-20251021.jpg
    ATHA Clarifies Technical Disclosure and Files an Amended Technical Report for Angilak

    accessnewswire.com

    2025-10-21 22:20:00

    VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") announces that, as a result of a review by the British Columbia Securities Commission ("BCSC"), the Company is issuing the following news release to clarify its disclosure regarding the Angilak Project. The BCSC review identified certain deficiencies in the Company's prior technical disclosure, including the treatment of historical mineral resource estimates and the disclosure of an exploration target model.

    https://images.financialmodelingprep.com/news/atha-energy-makes-major-new-discovery-along-the-rib-corridor-20250923.jpg
    ATHA Energy Makes Major New Discovery Along the Rib Corridor; Drills Best Exploration Hole to Date at The Angilak Uranium Project Intersecting 26.3 M of Composite Uranium Mineralization

    accessnewswire.com

    2025-09-23 07:00:00

    VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 23, 2025 / HIGHLIGHTS Major new discovery within the Mineralized RIB Corridor ("MRC"), the RIB North Discovery, located ~1.4 km along strike from the nearest drillhole at the RIB East Discovery (Figures 1 & 2); The first hole at RIB North, RIBN-DD-001, represents the most robust mineralized intersection to date within the MRC, and one of the most significant intersections within the Angilak Uranium Project (Figure 3); Drillhole RIBN-DD-001, intersected 26.3 m of total composite uranium mineralization including 1.9 m of high-grade2, over 10 zones from 345.55 m to 460.05 m. The hole intersected 13.6 m of continuous mineralization (from 426.25 m to 439.85 m) including 1.7 m of high-grade mineralization2 with maximum radioactivity of 55,730 counts per second (CPS1); Mineralization was initially intersected directly above the unconformity (located at 356.7m), extending into graphitic basement rock.

    https://images.financialmodelingprep.com/news/atha-energy-closes-oversubscribed-bought-deal-makes-third-new-20250918.jpg
    Atha Energy Closes Over-Subscribed Bought Deal - Makes Third New Discovery of 2025 Exploration Program at RIB West and Continues to Expand Mineralization at RIB East

    accessnewswire.com

    2025-09-18 08:50:00

    HIGHLIGHTS ATHA closes previously announced CAD $11.5 Million Over-Subscribed Bought Deal (See detail below, "Underwritten Private Placement"); First two drill holes completed at the RIB West Discovery successfully intersected uranium mineralization, including high-grade, over a strike length of ~340 m (Figure 2); Results represent the third new discovery of uranium mineralization - beyond the Lac 50 Deposit Trend - during the 2025 Angilak Exploration Program, within the Angikuni Basin along the 31 km RIB-Nine Iron Trend (Figure 1); RIB East Discovery is currently defined by eight mineralized drill holes, intersecting shallow uranium mineralization (7 million acres) in two of the world's most prominent basins for uranium discoveries - ATHA is well positioned to drive value. ATHA also holds a 10% carried interest in key Athabasca Basin exploration projects operated by NexGen Energy Ltd.

    https://images.financialmodelingprep.com/news/athira-pharma-announces-reverse-stock-split-20250911.jpeg
    Athira Pharma Announces Reverse Stock Split

    globenewswire.com

    2025-09-11 09:00:00

    BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.

    https://images.financialmodelingprep.com/news/athena-defines-geophysical-targets-and-mobilizes-field-crew-at-20250911.jpg
    Athena Defines Geophysical Targets and Mobilizes Field Crew at Laird Lake

    accessnewswire.com

    2025-09-11 07:00:00

    ADDITIONAL UNTESTED GOLD TARGETS IN RED LAKE, ONTARIO WHITE ROCK, BC / ACCESS Newswire / September 11, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce the identification of promising geophysical targets at its Laird Lake gold project in Ontario's prolific Red Lake Gold District. Recent analysis of historical geophysics has highlighted at least six distinct zones of electromagnetic (EM) anomalism (G1 to G6), complimenting the recently announced geochemical till anomalies (see press release dated September 4, 2025).

    https://images.financialmodelingprep.com/news/atha-files-updated-technical-reports-20250910.jpg
    ATHA Files Updated Technical Reports

    accessnewswire.com

    2025-09-10 19:55:00

    VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 10, 2025 / ATHA Energy Corp. (TSX.V:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), as a result of a review by the British Columbia Securities Commission, the Company is issuing the following news release to clarify certain disclosure. The Company announces today that it has filed: (i) an updated technical report in respect of its CMB property located in Newfoundland and Labrador, Canada dated July 8, 2025 and effective June 14, 2025 entitled "NI 43-101 Technical Report, Central Mineral Belt Property, Newfoundland and Labrador, Canada" prepared by Stefan Kruse, Ph.D.

    https://images.financialmodelingprep.com/news/athena-gold-successfully-completes-excelsior-springs-monetization-20250822.jpg
    Athena Gold Successfully Completes Excelsior Springs Monetization

    accessnewswire.com

    2025-08-22 07:00:00

    EXCELSIOR SPRINGS FULLY FUNDED FOR 2025 DRILLING PROGRAM WHITE ROCK, BC / ACCESS Newswire / August 22, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce that, further to its news release dated June 2, 2025, Mammoth Minerals Limited (ASX:M79) (formerly, Firetail Resources Limited) ("Mammoth" or "M79") has exercised its option to be able to earn an 80% interest in Athena's Excelsior Springs project in Nevada, USA (the "Excelsior" project), effective August 19, 2025 (the "Exercise Date"). In consideration.

    https://images.financialmodelingprep.com/news/athira-atha-q2-loss-narrows-74-20250807.jpg
    Athira (ATHA) Q2 Loss Narrows 74%

    fool.com

    2025-08-07 17:21:06

    Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.

    https://images.financialmodelingprep.com/news/atha-discovers-athabascastyle-highgrade-mineralization-at-rib-east-20250721.jpg
    ATHA Discovers Athabasca-Style High-Grade Mineralization at RIB East

    accessnewswire.com

    2025-07-21 07:00:00

    HIGHLIGHTS First three drill holes completed at RIB East Discovery successfully targeted stacked gravity, EM and structural anomalies (Figure 2), and intersected uranium mineralization, as part of the 2025 Angilak Exploration Program comprising 10,000 m of diamond drilling (Figure 1); Results represent the second new discovery of uranium mineralization - beyond the Lac 50 Deposit Trend - during the 2025 Angilak Exploration Program, within the Angikuni Basin along the 31 km RIB-Nine Iron Trend; Mineralization at RIB East Discovery is currently defined by three drill holes, all intersecting shallow uranium mineralization (10,000 CPS) over a continuous 1.0 m with max radioactivity of 30,730 CPS 1 (Figure 3a, b & 6) and a lower grade mineralized fracture intersected between 372 m and 372.6 m. RIBE-DD-003 was drilled 200 m along strike of RIBE-DD-002 and 150 m further into the hanging wall of an interpreted NW trending fault zone.

    https://images.financialmodelingprep.com/news/athena-gold-completes-till-survey-at-laird-lake-project-20250714.jpg
    Athena Gold Completes Till Survey At Laird Lake Project In Ontario's Red Lake Gold Camp

    accessnewswire.com

    2025-07-14 07:00:00

    WHITE ROCK, BC / ACCESS Newswire / July 14, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the successful completion of its comprehensive till survey at its Laird Lake gold project, located in Ontario's prolific Red Lake Gold District. The survey, completed ahead of schedule, marks a significant milestone in advancing the Company's exploration strategy on this highly prospective 4,158-hectare property, which spans over 10 km of the Balmer-Confederation Assemblage contact.